Q-omics provides the consensus-scored MTPN profile across patient tissues and cancer cell-line models. MTPN expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTPN is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, MTPN protein abundance shows 22,648 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, KIRP, and PDAC as cancer lineages where MTPN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTPN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTPN survival associations across molecular data types. MTPN RNA expression shows survival associations in the most cancer types (30), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTPN RNA expression–survival associations across cancer types. High MTPN expression shows unfavorable associations in MESO, PAAD, CESC, BLCA and KIRP, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify MESO as the clearest survival context for MTPN RNA expression.
This table summarizes MTPN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTPN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTPN shows lower tumor expression in THCA and higher tumor expression in KIRP, HNSC, LIHC, BLCA and BRCA. The KIRP box plot shows higher MTPN RNA expression in tumor versus normal tissue (log2 FC = +0.825, t-test p < 0.001).
This table shows molecular features associated with MTPN in patient tissues and cancer cell lines. In patient samples, MTPN shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTPN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
